The company’s consolidated revenue grew 13% YoY to Rs 6,304 crore, supported by steady patient volumes and margin improvement across its hospital and retail healthcare segments.
Steady momentum across core businesses
Revenue from Healthcare Services (HCS) — Apollo’s hospital business — rose 9% YoY to Rs 3,169 crore, with occupancy levels improving to 69%. The company reported an EBITDA of Rs 781 crore from this segment, up 8% YoY, while PAT rose 13% YoY to Rs 410 crore, reflecting efficiency gains and strong patient inflow for complex procedures.
The Apollo Health and Lifestyle Ltd (AHLL) segment, which operates clinics and diagnostics, continued to expand, with revenues up 17% to Rs 474 crore and EBITDA improving 21% to Rs 50 crore.
Meanwhile, Apollo HealthCo, which houses the company’s digital health platform Apollo 24|7 and pharma distribution business, posted revenues of Rs 2,661 crore, a 17% increase YoY, with EBITDA of Rs 110 crore. The platform’s gross merchandise value (GMV) stood at Rs 723 crore, underscoring Apollo’s growing digital footprint in healthcare delivery.
Chairman Dr Prathap C Reddy said the company’s continued investment in technology and innovation was helping strengthen patient care and drive operational efficiency.”We are proud to have touched over 200 million lives and earned trust across 185 nations. Our early adoption of the latest technology has led to over 51 lakh surgeries, 27,000 organ transplants, and 22,000 robotic surgeries,” Dr Reddy said.He added that Apollo was increasingly using AI-driven diagnostics and machine-learning platforms to personalise treatment for cancer and cardiovascular patients. The quarter also saw the company introduce South Asia’s first AI-based music therapy at the Apollo Proton Cancer Centre to improve the quality of life for cancer patients undergoing chemotherapy.
During the quarter, the Competition Commission of India (CCI) approved the company’s restructuring plan involving Apollo HealthCo, Keimed, and Apollo Healthtech, paving the way for Apollo to move forward with its reorganisation aimed at unlocking shareholder value.
The company also reiterated that capex intensity will continue to moderate after heavy investments in recent years, even as it continues expanding its hospital capacity and clinical capabilities.
